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Abstract
The decatenation G2 checkpoint is proposed to delay cellular progression from G2 into mitosis
when intertwined daughter chromatids are insufficiently decatenated. Previous studies indicated
that the ATM- and Rad3-related (ATR) checkpoint kinase, but not the ataxia telangiectasia-
mutated (ATM) kinase, was required for decatenation G2 checkpoint function. Here, we show that
the method used to quantify decatenation G2 checkpoint function can influence the identification
of genetic requirements for the checkpoint. Normal human diploid fibroblast (NHDF) lines
responded to the topoisomerase II (topo II) catalytic inhibitor ICRF-193 with a stringent G2 arrest
and a reduction in the mitotic index. While siRNA-mediated depletion of ATR and CHEK1
increased the mitotic index in ICRF-193 treated NHDF lines, depletion of these proteins did not
affect the mitotic entry rate, indicating that the decatenation G2 checkpoint was functional. These
results suggest that ATR and CHEK1 are not required for the decatenation G2 checkpoint, but may
influence mitotic exit after inhibition of topo II. A re-evaluation of ataxia telangiectasia (AT) cell
lines using the mitotic entry assay indicated that ATM was required for the decatenation G2
checkpoint. Three NHDF cell lines responded to ICRF-193 with a mean 98% inhibition of the
mitotic entry rate. Examination of the mitotic entry rates in AT fibroblasts upon treatment with
ICRF-193 revealed a significantly attenuated decatenation G2 checkpoint response, with a mean
59% inhibition of the mitotic entry rate. In addition, a normal lymphoblastoid line exhibited a 95%
inhibition of the mitotic entry rate after incubation with ICRF-193, whereas two AT
lymphoblastoid lines displayed only 36% and 20% inhibition of the mitotic entry rate. Stable
depletion of ATM in normal human fibroblasts with short hairpin RNA also attenuated
decatenation G2 checkpoint function by an average of 40%. Western immunoblot analysis
demonstrated that treatment with ICRF-193 induced ATM autophosphorylation and ATM-
dependent phosphorylation of Ser15-p53 and Thr68 in CHEK2, but no appreciable
phosphorylation of Ser139 on H2AX. The results suggest that inhibition of topo II induces ATM
to phosphorylate selected targets that contribute to a G2 arrest independently of DNA damage.
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Introduction
Cell cycle checkpoints represent mechanisms of control that 1) ensure the proper order of
the required events during the cell division cycle, 2) stabilize stalled or arrested DNA
replication forks, 3) provide more time for repair of DNA damage before DNA replication
and mitosis, and 4) induce growth arrest or apoptosis in response to genotoxic stress. Some
checkpoint genes such as ATR, CHEK1 and BRCA1 are essential, suggesting that
checkpoint signaling is required for successful and stable cell division. Other non-essential
checkpoint genes are familial cancer genes (e.g., TP53, ATM, CHEK2). Cell cycle
checkpoint responses are associated with oncogene-induced senescence, supporting a
hypothesis that checkpoints are barriers to the development of cancer. 1, 2 Since cell cycle
checkpoints slow growth and stabilize the genome, defects in these checkpoints are thought
to enhance clonal growth and genomic instability, thereby accelerating carcinogenesis. 3, 4 It
is of great interest to determine the mechanisms of cell cycle checkpoint function, how these
mechanisms may be disturbed during the multistage development of cancer, and the
consequences of checkpoint dysfunction. This paper specifically addresses the DNA
topoisomerase II-dependent decatenation G2 checkpoint.
Type II DNA topoisomerases (topo II) are homodimeric enzymes that can pass one DNA
duplex through another using a concerted process of DNA double-strand scission, duplex
passage, and double-strand re-ligation to remove DNA knots and separate intertwined or
catenated dimers. 5 Human cells express two related topo II enzymatic isoforms, α and β.6
Topo IIβ is not essential and is expressed constitutively, apparently providing a basal level
of decatenatory activity in quiescent cells. In contrast, topo IIα is cell cycle-regulated with a
pattern of mRNA expression similar to cyclin B1, CDK1 and PLK1, 7-9 all of which
regulate the progression from G2 into mitosis. Topo IIα is essential in mammals, 10
suggesting that topo IIβ is unable to compensate for the absence of topo IIα during cell
division. Catalytic inhibition of topo II and genetic attenuation or inactivation of topo IIα
decatenatory activity produce similar effects in human cells, such as undercondensation of
chromosomes and the impairment of segregation of sister chromatids at anaphase of mitosis.
11-15
The decatenation G2 checkpoint was first recognized when catalytic inhibitors of topo II
were shown to induce a G2 delay. 16-18 The bisdioxopiperazine ICRF-193 is a potent topo II
catalytic inhibitor 19 that holds the enzyme in a closed clamp form tethered to DNA, which
is unable to cleave DNA strands due to inhibition of its ATPase activity. 20,21 High
concentrations of ICRF-193 (>20 μM) induce a metaphase arrest, apparently by inhibiting
decatenation of sister chromatids and triggering a MAD2-dependent checkpoint. 13, 14, 22
Other studies have suggested that topo IIα is targeted to centromeres by the SUMO ligases
PIAS-γ and RanBP2, where it removes the final linkages between daughter chromatids at
the metaphase-anaphase transition. 14, 22-25 Lower concentrations of ICRF-193 do not
induce prolonged metaphase arrest, as most mitotic cells eventually complete mitosis.
However, after treatment with these lower concentrations of ICRF-193 (1-4 μM), NHDFs
display a severe delay in the progression from G2 into mitosis, 16, 26 causing up to a 95%
reduction in the percentage of mitotic cells in asynchronous cultures within 2 h of exposure
to the drug. 17, 27 As the topo II catalytic inhibitors do not produce topo II-associated
cleaved DNA complexes, nor appreciable numbers of DNA strand breaks, 13, 16, 17, 28 the
G2 delay that is induced by such drugs appears to differ from the DNA damage G2
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checkpoint response. Previous studies demonstrating that BRCA1 was required for
ICRF-193-induced mitotic inhibition suggested that the G2 delay was an active process, and
was designated the decatenation G2 checkpoint. 18
A study of human lung cancer cells described three lines that responded to ICRF-193 with a
G2 delay, but without inhibiting the kinase activity of the mitosis promoting factor (MPF),
which is composed of the cyclin B1 and CDK1 (cdc2) proteins. 28 Since activation of the
DNA damage G2 checkpoint inhibits MPF, this result supported the hypothesis that the
decatenation G2 checkpoint is distinct from the DNA damage G2 checkpoint and confirms a
prior report indicating that the decatenation G2 checkpoint is enforced by retaining active
MPF in the cytoplasm where it cannot induce mitosis. 26,29, 30
Although ICRF-193 cannot be consistently shown to induce γ-H2AX foci as a marker of
replication stress and DNA double strand breaks (dsbs), 13, 28 the drug did induce
phosphorylation of ATM in the lung cancer cell lines with effective decatenation G2
checkpoint function. 28 Canonically, ATM is activated by treatments that induce DNA dsbs.
However, it can also be activated by alterations in chromatin structure, such as those
produced by incubating cells in high-salt medium, 31 or by treatment with the DNA
intercalating drug and topo II catalytic inhibitor chloroquine. 32, 33 The antibiotic
ciprofloxacin, which is a topo II inhibitor commonly used to treat mycoplasma
contamination in cultured cell lines, has been shown to induce phosphorylation of ATM and
trigger G2 arrest without induction of γ-H2AX. 34 These results suggest that ATM may be
activated under conditions that trigger the decatenation G2 checkpoint in response to altered
states of chromatin that develop upon catalytic inhibition of topo II. In this paper, we have
re-examined the roles of ATM, CHEK1, and ATR in the decatenation G2 checkpoint
response to the topo II catalytic inhibitor ICRF-193 using assays that monitor mitotic index,
mitotic entry rates, and G2 arrest.
Results
ATR and CHEK1 are not required for decatenation G2 checkpoint function
Due to the recent reports suggesting a role for topo II in both G2 arrest and mitotic arrest,
decatenation G2 checkpoint function was quantified using two distinct flow cytometry
methods. The first method, termed the mitotic index assay, quantifies the reduction in
mitotic index two hours after a15-min incubation with 4 μM ICRF-193 relative to vehicle
control-treated cells. Inhibition of topo II blocks decatenatory activity in G2 cells and
activates a checkpoint that delays progression of G2 cells into mitosis. Since cells already in
mitosis divide within two hours after the drug treatment, catalytic inhibition of topo II
should cause the mitotic cell compartment to empty. However, depletion of topo IIα or
inhibition of topo II activity with catalytic inhibitors can block centromere separation, even
in cells with a disruption or depletion of cohesion, and delay the completion of mitosis. 14,
22-24 Since topo IIα appears to be required at the metaphase-to-anaphase transition to
decatenate centromeric DNA and may influence the length of mitosis, a second method,
referred to as the mitotic entry assay, was employed to determine decatenation G2
checkpoint function. The mitotic entry assay relies on the microtubule depolymerization
inhibitor colcemid to prevent mitotic exit, allowing a strict measure of the progression from
G2 into mitosis and eliminating confounding factors, such as the rate of mitotic exit, from
the analysis. Cells are accumulated in colcemid over a period of two, four, or six hours in
the presence or absence of the catalytic topo II inhibitor ICRF-193, and a mitotic entry rate
is calculated from the slope of the resulting line by linear regression.
ATR and CHEK1 have previously been reported to be required for decatenation G2
checkpoint function. 18, 43 Studies investigating the role of ATR have relied on an SV40-
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transformed human fibroblast line over-expressing a kinase-inactive ATR protein.18 The
role of CHEK1 was previously examined by genetic inactivation in DT40 chicken
erythroleukemia cells.43 To determine the role of ATR and CHEK1 in decatenation G2
checkpoint function in NHDFs, non-targeting control (NTC) siRNA, ATR siRNA, or
CHEK1 siRNA were electroporated to deplete protein expression. Electroporation of siRNA
was effective in depleting the ATR and CHEK1 proteins (Fig. 1A and 2A), producing mean
reductions of 90% and 95%, respectively.
NTC siRNA-treated NHDFs responded to the topo II inhibitor with a significant reduction in
mitotic index (Fig. 1B and 2B); two hours after drug treatment the mitotic index was
reduced by about 80% compared to the vehicle control-treated cells. This value is similar to
values previously observed for the NHF1hTERT fibroblast line,18 suggesting that the
conditions of electroporation of siRNA did not affect the determination of mitotic inhibition
after treatment with ICRF-193. In contrast, ATR-depleted NHDFs displayed an attenuated
reduction of the mitotic index; an average 40% reduction in mitotic index was observed after
treatment with ICRF-193 (Fig. 1B). Due to large inter-experimental variability, the
difference between the NTC-treated and ATR-depleted NHDF mean mitotic index reduction
was not statistically significant. In contrast, depletion of CHEK1 produced a significant
increase in the mitotic index in ICRF-193-treated cells when compared to vehicle control-
treated cells (Fig. 2B). These results suggested that ATR and CHEK1 were influencing the
number of mitotic cells after topo II catalytic inhibition.
In contrast to the mitotic index assay results, depletion of ATR and CHEK1 did not affect
the ICRF-193-induced G2 arrest (Fig. 1C and 2C). As previously described, the increment of
mitotic NHDFs upon addition of colcemid was delayed by about 2 h. 44 Thereafter, mitotic
indices of ATR- and CHEK1-depleted NHDFs increased by 1-3% per hour during
incubation with colcemid and the drug solvent DMSO. Addition of colcemid and 4 μM
ICRF-193 to NHDFs severely delayed the accumulation of mitotic cells with an average
inhibition of 95% in three different ATR-depleted NHDF lines (Fig. 1C and data not
shown). The average inhibition of mitotic entry relative to DMSO-treated controls was 97%
in three different NHDF lines that had been depleted of CHEK1 (Fig. 2C and data not
shown). Since NHDFs depleted of ATR and CHEK1 responded to ICRF-193 with a
stringent G2 arrest equivalent to that seen in NTC siRNA-treated cells, we concluded that
ATR and CHEK1 were not required for a functional decatenation G2 checkpoint.
It was possible that the 4 μM concentration of ICRF-193 saturated signaling of the
decatenation G2 checkpoint and thereby obscured a partial contribution of ATR. To test for
more subtle effects of ATR on the decatenation G2 checkpoint, cells were depleted of ATR
and the mitotic entry assay was performed with increasing concentrations of ICRF-193 in
the range of 125-500 nM. As shown in Figure 1D, ATR-depleted cells displayed the same
sensitivities to ICRF-193-induced G2 delay as NTC siRNA-treated cells at all tested
concentrations of the drug. A similar result was obtained with CHEK1-depleted cells (data
not shown).
ATM is required for decatenation G2 checkpoint function
Given the previous results that ATR was not required for decatenation G2 checkpoint
function, and earlier studies suggested that the checkpoint could be overridden by the
general kinase inhibitor caffeine, it was important to reassess the role of ATM in the
decatenation G2 checkpoint.18 Three NHDF lines were compared to three AT fibroblast
lines using the mitotic index reduction assay and the mitotic entry assay. NHDFs displayed a
significant 63-83% reduction in the mitotic index upon treatment with ICRF-193 with an
average reduction of 75% (Fig. 3A and 3B). The AT fibroblast lines displayed less mitotic
inhibition after ICRF-193 treatment with an average inhibition of mitosis of 15% (Fig. 3A
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and 3B), indicating that the AT fibroblasts displayed a significant attenuation in mitotic
reduction upon drug treatment.
As previously demonstrated for NHDFs, AT fibroblasts accumulated in mitosis in the
presence of colcemid; the mitotic index increased from 1-2% at the time of addition of
colcemid to 6-10% after 6 h. In the NHF10hTERT line depicted in Figure 3C, the
accumulation of mitotic cells in colcemid was abolished during incubation with ICRF-193.
Under the same conditions, ICRF-193-treated AT fibroblasts exhibited an accumulation of
mitotic cells over time (Fig. 3C). Although there was substantial experimental variability in
the AT1 line, the mean reduction in the rate of progression from G2 to M in the presence of
ICRF-193 was 65%, similar to the mean values acquired for the AT2 and AT3 lines (Fig.
3D). Among the three different AT fibroblast lines, the average inhibition of the mitotic
entry rate upon ICRF-193 treatment was 59%, as compared to an average 98% inhibition of
mitotic entry rate in three NHDFs. These results suggested that the AT lines displayed a
significant (∼40%) attenuation of decatenation G2 checkpoint function.
Our prior analysis of AT cells, which showed an average of 60% inhibition in response to
ICRF-193 treatment, employed a set of lymphoblastoid lines and was measured with the
mitotic index assay.18 It was therefore necessary to re-examine those lines with the mitotic
entry rate assay. Two AT lymphoblastoid lines and one normal lymphoblastoid line that
were included in the prior analysis were analyzed. The normal and AT lymphoblastoid lines
both responded to colcemid with a steady increase in mitotic cells, and the accumulation of
mitotic cells was 95% blocked in the normal line upon addition of ICRF-193 (Fig. 4A). In
contrast, the two AT lymphoblastoid lines allowed the accumulation of mitotic cells during
incubation with ICRF-193 (Fig. 4A). Rates of mitotic entry in the ICRF-193-treated AT
cells were reduced by 36% and 20% in comparison to values obtained in the DMSO-treated
controls (Fig. 4B), indicating that the AT lymphoblastoid lines also displayed a severe defect
in decatenation G2 checkpoint function.
Although several studies have indicated that ICRF-193 does not induce topo II-associated
DNA cleavage complexes, 16, 17, 45 other studies have demonstrated that ICRF-193 can
activate DNA damage response elements. 28, 46 To explore this issue further, the fibroblast
and lymphoblastoid lines were treated with ICRF-193 and examined for the expression of
several markers of the DNA damage response. Lymphoblasts were incubated for 3 or 6 h
with colcemid with and without ICRF-193 to explore the activation of the canonical DNA
damage checkpoint proteins CHEK2, CHEK1, p53, and H2AX. As a positive control for
activation of DNA damage checkpoint signaling, normal lymphoblasts were treated with 12
μM etoposide, and the induction of γH2AX, phospoho-Ser15 p53, and phospho-Thr68
CHEK2 was observed (Figure 5A). In the normal lymphoblasts there was no increment of
phospho-Ser345 CHEK1 after 3 h of ICRF-193 treatment, and only a small increment of
CHEK1 activation over colcemid alone after 6 h. No increment of phospho-CHEK1 was
seen in AT cells under any treatment condition. Two downstream targets of activated ATM
are CHEK2 and p53, and treatment with ICRF-193 induced phosphorylation of both in
normal lymphoblasts, but not those collected from AT patients. These results indicate that
ICRF-193 induced a selective phosphorylation of ATM substrates CHEK2 and p53, but not
H2AX in lymphoblastoid cell lines. Very similar results were obtained with the NHDFs
incubated with 4 μM ICRF-193 for three hours (Fig. 5B.).
Given that AT cells may harbor genetic mutations other than ATM, we further explored the
role of ATM in the decatenation G2 checkpoint in an NHF1hTERT fibroblast line with
stable depletion of ATM protein using the mitotic entry rate assay. The control
NHF1hTERTs (expressing a short hairpin directed towards LacZ) responded to ICRF-193
with 97% inhibition of mitotic entry (Fig. 6A). The ATM-depleted fibroblasts displayed a
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significant attenuation of the ICRF-193-induced G2 arrest with a rate of mitotic entry
approximately 40% of the control, similar to the values recorded with AT fibroblast and AT
lymphoblast lines (Fig. 3 and Fig. 4). Furthermore, the NHF1hTERT-shLacZ fibroblast line
responded to the topo II poison etoposide with substantial induction of phospho-Ser1981
ATM (Fig. 6B). Treatment with ICRF-193 produced a modest increase in phospho-Ser1981
ATM in NHDF and lymphoblastoid lines, but not in ATM-defective or ATM-depleted
fibroblast or lymphoblastoid lines.
It has recently been suggested that depletion of topo IIα severely attenuates the ICRF-193-
induced decatenation G2 checkpoint (Bower and Kaufmann, unpublished data).47 Thus, it
was possible that the attenuation of decatenation G2 checkpoint function in AT cells was
related to a reduction in the expression of topo IIα. Western immunoblot analysis confirmed
that AT fibroblasts, AT lymphoblasts, and ATM-depleted fibroblasts expressed both topo
IIα and topo IIβ (Fig. 6B). Although the levels of topo IIα varied among the cell lines, AT
cells displayed similar or higher levels of topo IIα than the NHDFs, indicating that the
significant attenuation of decatenation G2 checkpoint function in AT cells and ATM-
depleted cells was not associated with reduced expression of topo IIα. However, we cannot
rule out the possibility that truncation or depletion of ATM may influence one of the many
post-translational modifications found on the topo IIα protein.
Discussion
The results presented here suggest that decatenation G2 checkpoint function is more
accurately quantified by measuring the rate of mitotic entry, rather than measuring the
mitotic index at a single time point. The mitotic index assay relies upon two events to detect
decatenation G2 checkpoint function: G2 arrest and mitotic exit. Given that topo IIα
contributes to a decatenation reaction at centromeres that suppresses a MAD2-dependent
metaphase checkpoint, 13, 22 treatment with ICRF-193 can induce a metaphase delay that
blocks mitotic exit. The mitotic entry rate assay quantifies the rate of G2/M progression, and
is not influenced by the ICRF-193-induced metaphase arrest or mitotic exit rates. By
applying the improved mitotic entry rate assay, it was clear that ATR and CHEK1 are not
required for decatenation G2 checkpoint function, whereas depletion or truncation of ATM
significantly attenuated the checkpoint response in NHDFs and lymphoblasts, respectively.
The prior study of ATR function in the decatenation G2 checkpoint utilized an SV40-
transformed human fibroblast line with inducible expression of kinase-inactive ATR.18
SV40-transformed human fibroblast lines typically display highly aneuploid genomes due to
a phase of severe telomere crisis before establishment of immortality. 49 DNA damage
checkpoints acting in G1, S, and G2 may be defective in SV40-transformed and large T
antigen-transformed lines. 50, 51 It is possible that the over-expression of kinase-inactive
ATR and incubation with ICRF-193 in the SV40-transformed line disrupted centromeric
decatenation and induced a metaphase arrest.
The complicated biology of SV40-transformed immortal human cell lines with aneuploid
genomes requires that caution should be applied when interpreting features of cell cycle
regulation in such immortalized lines. The telomerase-expressing diploid human fibroblast
lines were developed to overcome this problem. Transduction of hTERT to immortalize
human fibroblasts generates a cell culture model with extended-lifespan, stable diploid
genomes, and retention of all DNA damage checkpoint functions at levels equivalent to
those measured in telomerase-negative, parental fibroblast strains.30, 35 Severe depletion of
ATR in three diploid normal human fibroblast lines had no effect on ICRF-193-induced G2
arrest (Fig.1 and data not shown). As depletion of protein expression does not always
produce the same phenotype as drug-induced over-expression of kinase-inactive mutants, 52
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it is conceivable that over-expression of the kinase-inactive ATR allele produced
biochemical alterations within SV40-transformed cells that affected mitotic entry or exit
after treatment with ICRF-193.
The prior analysis in DT40 cells showed that 1 μM ICRF-193 reduced the rate of
accumulation of mitotic cells during incubation with nocodazole by 15% relative to control
but, in cells with genetic depletion of CHEK1, ICRF-193 had no effect on mitotic
accumulation.43 The DT40 cells are known to display defects in DNA damage G1
checkpoint function, 53 and their modest response to ICRF-193 suggests they may express a
defective decatenation G2 checkpoint. In diploid human fibroblast lines, 0.5 μM ICRF-193
reduced the rate of mitotic entry by 75% relative to control (Fig. 1D) and 4 μM produced a
97-99% inhibition. Fibroblasts depleted of CHEK1 responded to 4 μM ICRF-193 with a
97% reduction in the mitotic entry rate, indicating that CHEK1 was not required for
decatenation G2 checkpoint function. Equivalent depletion of CHEK1 in normal fibroblasts
produced a severe attenuation of the intra-S checkpoint response to UV irradiation, 54
demonstrating that the degree of depletion of CHEK1 protein was sufficient to inhibit DNA
damage checkpoint signaling.
The prior studies of ATM and decatenation G2 checkpoint function used either
lymphoblastoid lines with the mitotic index assay, 18 or an SV40-transformed AT fibroblast
line with the mitotic entry rate assay. 40 The telomerase-expressing AT fibroblast lines
display canonical defects in DNA damage checkpoint functions, hypersensitivity to ionizing
radiation, 36 and significantly less mitotic inhibition and G2 delay than normal fibroblast
lines when treated with ICRF-193 (Fig. 3). In addition, AT lymphoblastoid and ATM-
depleted NHF1hTERTs displayed similar defects in decatenation G2 checkpoint function
(Fig. 4A and Fig. 6A). Taken together, the biological data presented here strongly support
the hypothesis that ATM contributes to decatenation G2 checkpoint function.
A few studies have questioned the existence of the decatenation G2 checkpoint. One study
showed that high concentrations of ICRF-193 caused Indian muntjac cells first to delay in an
early phase of mitosis called antephase and then to fall back into a G2–like state.55
ICRF-193-treated muntjac cells also expressed γH2AX as a putative marker of DNA dsbs,
55 although recent studies suggest that γH2AX may not be specific for DNA dsbs. 56, 57
Another study examined DNA damage response markers in diploid human fibroblasts and
HeLa cells after treatment with ICRF-193. 46 Elements of ATM-dependent DNA damage
response were recognized, including activation of CHEK2 and expression of γH2AX. The
demonstration of γH2AX in ICRF-193-treated cells has not been reproducible, and HeLa
cells examined by the mitotic entry rate assay display an attenuated decatenation G2
checkpoint (Bower and Kaufmann, unpublished data). In addition, Skoufias et al. found that
while both IR and etoposide induced γH2AX in HeLa cells as expected, ICRF-193 did not,13
and neither Nakagawa et al. nor Luo et al. were able to detect γH2AX in human cancer lines
after treatment with ICRF-193. 28, 47 The ultrasensitive method of alkaline elution
chromatography did not detect DNA damage in ICRF-193-treated diploid human fibroblasts,
17 and we have been unable to detect appreciable activation of γH2AX in ICRF-193-treated
NHDFs by flow cytometry or immunofluorescence (Bower and Kaufmann, in preparation).
However, cells that evaded the decatenation G2 checkpoint after treatment with ICRF-193
displayed chromosomal aberrations, 26 which may be recognized as DNA dsbs upon mitotic
exit and return to interphase.
The analysis of DNA damage response biomarkers reported here indicated that ATM
signaling was induced by ICRF-193. Remarkably, treatment with ICRF-193 induced an
ATM-dependent phosphorylation of p53 and CHEK2, but not H2AX. This result is
reminiscent of recent reports showing that the topo II catalytic inhibitors chloroquine and
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ciprofloxacin can activate ATM without phosphorylation of H2AX. 33, 34 Thus, it appears
that catalytic inhibitors of topo II may induce a conformational change in chromatin that
activates ATM. This method of activation of ATM differs from the response to DNA dsbs,
as γH2AX is not induced.
It has been recently demonstrated that Ser1524 in topo IIα is phosphorylated in HT1080
fibrosarcoma cells, and this phosphorylation is required for ICRF-193-induced G2 arrest. 47
Cells in which endogenous topo IIα was replaced with ectopic topo IIα containing a non-
phosphorylatable alanine at this position failed to arrest in G2 when treated with ICRF-193,
and entered mitosis with severely entangled sister chromatids. The phospho-Ser1524 in topo
IIα was bound by the BRCT repeat of the checkpoint mediator protein MDC1 and this
binding was stimulated by inhibition of topo IIα with ICRF-193. Furthermore, depletion of
MDC1 attenuated the ICRF-193-induced G2 arrest. It is interesting to note that MDC1 is
phosphorylated by ATM and serves to recruit ATM to γH2AX on chromatin at the sites of
DNA dsbs. 58 As ICRF-193 does not induce γH2AX, MDC1 may recruit ATM to
catalytically inactive topo IIα, upon exposure to ICRF-193, chloroquine, and/or
ciprofloxacin.
Materials and Methods
Cell lines and cell culture
To avoid idiosyncratic biological responses in cell culture models, three lines of NHDFs
(NHF1hTERT, NHF3hTERT, and NHF10hTERT) and three lines of AT fibroblasts
(designated AT1, AT2 and AT3) were analyzed. The properties of these lines have been
described. 35, 36 NHDFs were isolated from neonatal foreskin and immortalized by the
overexpression of hTERT as described previously.35 Each fibroblast line was isolated from
a different individual and each experiment was performed in all three NHDF or AT
fibroblast lines to assess biological reproducibility as well as inter-individual genetic
variation. The three telomerase-expressing normal lines displayed diploid karyotypes
without chromosomal aberrations and produced highly stereotypic patterns of response to
DNA damage, with effective DNA damage G1 and G2 checkpoints. 35 The three telomerase-
expressing AT lines displayed marker chromosomal aberrations but retained near diploid
karyotypes. The AT lines also displayed significant defects in DNA damage G1 and G2
checkpoint responses to ionizing radiation-induced DNA dsbs. 36 Human lymphoblastoid
lines were obtained from the Coriell Institute including two lines from AT patients
(GM3189 and GM9582) and one line from a normal healthy donor (GM3714).37 The
NHF1hTERT fibroblast line with stable expression of ATM shRNA or LacZ shRNA were a
kind gift from Richard Paules and were established as described.38 NHDF and AT fibroblast
lines were grown in DMEM (Invitrogen, Carlsbad, CA) and supplemented with 15% FBS
(Sigma, St. Louis, MO) and 2 mM L-Glutamine (Invitrogen, Carlsbad, CA).
Lymphoblastoid lines were grown in RPMI medium and supplemented with 15% FBS.
Cultures were maintained at 5% CO2 and 37°C. All experiments were performed on
fibroblast cultures that had undergone less than 100 population doublings. Periodic tests for
mycoplasma contamination using a commercial kit (Gen-Probe, San Diego, CA) were
negative.
Depletion of ATR and CHEK1 by siRNA
The non-targeting control (NTC) siRNA sequence directed towards the firefly luciferase
mRNA, the ATR siRNA SMARTpool, and the CHEK1 siRNA were obtained from
Dharmacon (Dharmacon, Inc., Lafayette, CO). NHDFs were electroporated using an NHDF
Nucleofector Kit (Amaxa, Inc., Gaithersburg, MD), and allowed to recover for 48 hours
before assaying the biological effects, when depletion of the target protein was maximal.
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Western immunoblot analysis was used to confirm protein depletion for each individual
experiment at the time of assay.
Mitotic inhibition assay of decatenation G2 checkpoint
Asynchronous cultures of diploid human fibroblasts were treated briefly (15 min) with 4 μM
ICRF-193 then incubated in drug-free reserved medium for 2 h before cell harvest.27 Mitotic
cells were quantified by flow cytometry using a primary mouse monoclonal antibody to
mitosis-associated phospho-histone H3 and a fluorescein isothiocyanate-labeled secondary
rabbit antibody to the mouse primary antibody. 39
Mitotic entry assay of decatenation G2 checkpoint
Electroporated fibroblasts were plated at a density of 106 cells per 10 cm2 dish (day 0), and
fed with fresh medium on day 1. On day 2, cells were treated with 100 ng/mL colcemid (to
collect cells in mitosis), and either 0.1% DMSO or 4 μM ICRF-193 for 2, 4, and 6 hours.
Fibroblasts were then trypsinized into a single cell suspension and fixed with 95% ethanol:
5% acetic acid overnight at 4° C. An anti-phospho Ser 10 histone H3 primary antibody
(Millipore, Billerica, MA) and an anti-mouse FITC labeled secondary (Santa Cruz
Biotechnology, Santa Cruz, CA) were used to identify mitotic cells. Propidium iodide
(Sigma, St. Louis, MO) was used to measure DNA content. Samples were measured on a
Dako CyAN ADP instrument at the Flow Cytometry Core Facility at UNC-CH. Flow
cytometry samples were analyzed using Summit 4.3 plots to quantify the percentage of
fibroblasts with 4N DNA content that also were labeled with phospho-Ser10 histone H3, a
specific marker of mitosis. The percentage of mitotic cells for each sample was plotted
against time and the resulting slope of the line was used to measure the rate of entry into
mitosis (% of fibroblasts entering mitosis per hour).
Western immunoblot analysis
Antibodies were obtained that recognized phospho-Ser1981 ATM (Epitomics, Burlingame,
CA or Rockland Immunochemicals, Gilbertsville, PA), phospho-Ser139 H2AX (Millipore,
Billerica, MA), phospho-Ser345 CHEK1 (Cell Signaling Technology, Danvers, MA),
phospho-Ser15 p53 (Cell Signaling Technology, Danvers, MA), ATR (Santa Cruz, Santa
Cruz, CA), total ATM (Bethyl, Montgomery, TX), topo IIα (BD Biosciences, San Jose,
CA), topoII β (BD Biosciences, San Jose, CA), and phospho-Thr68 CHEK2 (Cell Signaling
Technology, Danvers, MA). Conditions for protein extraction, polyacrylamide gel
electrophoresis, and immunoblot analysis using enhanced chemiluminescence and X-ray
film exposure were as previously described. 39, 41 For histone analyses, cells were heated to
100°C in gel-loading buffer before electrophoresis. For fluorescence detection of western
immunoblots, a secondary anti-mouse Cy3or Cy5 labeled antibody was obtained from GE
Healthcare (Piscataway, NJ) and fluorescence was measured on a Typhoon 9400 (GE
Healthcare, Piscataway, NJ). Pixel intensity values from scanned X-ray film or fluorescence
intensities were used to quantify protein depletion by siRNA. 42
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Figure 1. ATR is not required for decatenation G2 checkpoint function
Diploid fibroblast lines were electroporated with non-targeting control (NTC) siRNA or
siRNA directed towards ATR. A. Cells were harvested for immunoblot analysis of ATR
protein levels at 48 h after electroporation when protein depletion was maximal. Treatment
with 1.5 Gy IR 30 min before harvest did not affect expression of ATR. B. NTC-treated and
ATR-depleted NHDFs were incubated with 4 μM ICRF-193 for 15 min, then further
incubated in drug-free medium for 2 h before cell harvest for quantification of phospho-
histone H3+ mitotic cells by flow cytometry. Results show the mean reductions in the
mitotic index in ICRF-193-treated NHF1hTERT cells relative to DMSO-treated controls
(+sd, n=4). Depletion of ATR appeared to attenuate the ICRF-193-induced inhibition of the
emptying of the mitotic compartment. C. NTC-treated and ATR-depleted NHF1hTERT cells
were incubated with 100 ng/ml colcemid for 0-6 hours and the percentage of mitotic cells
was measured by flow cytometry. Inclusion of 4 μM ICRF-193 during incubation with
colcemid blocked the accumulation of mitotic cells in ATR-depleted fibroblasts, suggesting
that ATR is not required to prevent mitotic entry in the presence of catalytically inactive
topo II. Results are representative of three independent experiments. D. ATR-depleted
NHF1hTERT fibroblasts were incubated for 6 h with colcemid and increasing
concentrations of ICRF-193. The percentage of mitotic cells that accumulated with colcemid
alone was determined, and the mitotic index in ICRF-193-treated cells is expressed as a
fraction of the DMSO-treated control value. ATR-depleted cells displayed the same
sensitivity to ICRF-193-induced G2 delay as the NTC-treated counterparts, suggesting that
ATR does not play a role in decatenation G2 checkpoint function, even at lower doses of
ICRF-193 exposure.
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Figure 2. CHEK1 is not required for decatenation G2 checkpoint function
Diploid fibroblast lines were electroporated with non-targeting control (NTC) siRNA or
siRNA directed towards CHEK1. A. Cells were harvested for immunoblot analysis of
CHEK1 protein levels at 48 h after electroporation when protein depletion was maximal.
Control and CHEK1-depleted cells were treated with 1.5 Gy IR or 6 J/m2 UVC 30 min
before cell harvest to test for ATM-dependent phosphorylation of CHEK2 and ATR-
dependent phosphorylation of CHEK1. B. NTC-treated and CHEK1-depleted NHDFs were
subjected to the mitotic index reduction assay as described in Figure 1B. (+sd, n=3).
Depletion of CHEK1 also appeared to attenuate the ICRF-193-induced inhibition of the
mitotic compartment emptying. C. NTC-treated and CHEK1-depleted NHF1hTERT cells
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were subjected to the mitotic entry assay described in Figure 1C. Similar to the ATR-
depleted fibroblasts, 4 μM ICRF-193 blocked the accumulation of mitotic cells in the
CHEK1-depleted fibroblasts, suggesting that CHEK1 is not required for decatenation G2
checkpoint function. Results are representative of three independent experiments.
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Figure 3. AT fibroblasts display an attenuated decatenation G2 checkpoint
A. Normal and AT fibroblast lines were incubated with 4 μM ICRF-193 for 15 min, and for
an additional 2 h in drug-free medium before quantification of mitotic index by flow
cytometry. The mitotic index in ICRF-193-treated cells was expressed as a percent of the
mitotic index in DMSO-treated controls (+sd; NHF1, n=5; NHF3, n=4; NHF10, n=7; AT1,
n=8; AT2, n=3; AT3, n=3). B. Mean inhibitions of mitotic index after treatment with
ICRF-193 among normal and AT fibroblast lines (+sd, n=3). The attenuated inhibition of
mitotic emptying in the AT fibroblasts suggested that ATM may play a role in mitotic entry
or mitotic exit. C. Normal and AT fibroblasts were incubated with colcemid for 0-6 h with
0.1% DMSO (closed symbols) or 4 μM ICRF-193 (open symbols) and harvested for flow
cytometric analysis of mitotic cells. Results are representative of at least four independent
experiments. D. Bar graphs representing the mean fraction of cells evading the ICRF-193-
induced G2 arrest as compared to DMSO-treated controls (NHF10, n=5; AT1, n=5; AT2,
n=4; AT3, n=4). AT fibroblasts exhibited an attenuated response to treatment with
ICRF-193, indicating that ATM may play a role in the decatenation G2 checkpoint.
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Figure 4. AT lymphoblasts exhibit a defective decatenation G2 checkpoint
A. Normal (GM3714) and AT lymphoblasts (GM3189, GM9582) were incubated with
colcemid for 0-6 h with or without 4 μM ICRF-193 then harvested for quantification of
mitotic entry rates by flow cytometry. Results are representative of three independent
experiments. B. Bar graphs depicting the average percentages of cells evading the
ICRF-193-induced G2 arrest (+sd, n=2).
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Figure 5. ICRF-193 induces ATM-dependent checkpoint signaling, but not DNA damage in
human fibroblasts and lymphoblasts
A. Normal and AT lymphoblasts were treated with colcemid and DMSO or ICRF-193 for 3
or 6 h and harvested for western immuno-blot analysis. Equal amounts of cell lysate protein
were analyzed for phospho-Ser 345 CHEK1, phospho-Thr 68 CHEK2, and phospho-Ser 15
p53. For γH2AXdetection, equal numbers of cells were boiled in gel loading buffer before
SDS-PAGE analysis. ICRF-193 treatment induced ATM-dependent phosphorylation of Thr
68-Chk2 and Ser 15-p53, but not γH2AX. A small increment of phophorylated Ser345-Chk1
is observed in the normal lymphoblasts upon 6 hr of ICRF-193 treatment, suggesting that
lymphoblasts may activate low levels of Chk1 after a prolonged exposure to ICRF-193.
Normal lymphoblasts treated with 12 μM etoposide for 6 h were analyzed as a positive
control for DNA damage-induced signaling responses. B. Normal and AT fibroblast lines
were treated with DMSO or 4 μM ICRF-193 for 3 h and harvested for western immunoblot
analysis. Levels of γH2AX and phospho-Ser345 Chk1 remained low in all fibroblast lines
examined. Similar to the normal lymphoblasts described in Fig. 1A, an ATM-dependent
phosphorylation of Thr 68-Chk2 and Ser15-p53 were detected upon treatment with
ICRF-193. NHF1hTERTs treated with 12 μM etoposide for 6 h were analyzed as a positive
control for DNA damage.
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Figure 6. ATM is required for decatenation G2 checkpoint function
The NHF1hTERT fibroblast line was infected with a retrovirus to express LacZ or ATM
shRNA. 38 A. ICRF-193-induced G2 arrest was quantified using the mitotic entry assay
(described in Fig. 1 and 2). ATM-depleted cells and LacZ-transduced control cells were
incubated with colcemid for 0-6 h with DMSO or 4 μM ICRF-193 and harvested for
quantification of mitotic cells by flow cytometry. The average percentages of cells evading
the ICRF-193-induced G2 arrest are shown (+sd, n=3). B. Western immunoblot showing
expression of ATM, phospho-ATM, topo IIα and topo IIβ in human fibroblasts and
lymphoblasts. Cells were treated with 0.1% DMSO (D), 4 μM ICRF-193 (I) or 4 μM
etoposide (E) for three hours before harvest. Equal amounts of cell protein were loaded for
electrophoretic separation and immunoblot analysis. ICRF-193 induced phosphorylation of
ATM in the shLacZ NHDFs, but not the shATM NHDFs.
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